Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31444457 | 1.00 | CES2 (0.38) | CES2CES1BCHESLC6A2SLC6A4 | |
| SCHEMBL30769070 | 0.79 | — | — | |
| SCHEMBL182562 | 0.79 | — | — | |
| SCHEMBL28095225 | 0.78 | CES2 (0.44) | CES2CES1BCHESLC6A2SLC6A4 | |
| SCHEMBL1446076 | 0.77 | CES2 (0.36) | CES2CES1 | |
| SCHEMBL1863530 | 0.76 | TAAR1 (0.32) | CES2CES1 | |
| SCHEMBL31444326 | 0.76 | TAAR1 (0.32) | CES2CES1 | |
| SCHEMBL1125226 | 0.76 | ACHE (0.37) | CES2CES1 | |
| SCHEMBL1445913 | 0.75 | CES2 (0.38) | CES2CES1BCHESLC6A2SLC6A4 | |
| Bromide SCHEMBL1446078 | 0.75 | CES2 (0.38) | CES2CES1BCHESLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609574-B2 | In situ olefin polymerization catalyst system | PROMERUS LLC (US) | 2013-12-17 | — | — | US | claimed |
| EP-2296811-A2 | IN SITU OLEFIN POLYMERIZATION CATALYST SYSTEM | Promerus, LLC (US) | 2011-03-23 | — | — | EP | claimed |
| US-20090270247-A1 | IN SITU OLEFIN POLYMERIZATION CATALYST SYSTEM | PROMERUS LLC (US) | 2009-10-29 | — | — | US | claimed |
| WO-2009132240-A2 | IN SITU OLEFIN POLYMERIZATION CATALYST SYSTEM | PROMERUS LLC (US) | 2009-10-29 | — | — | WO | claimed |
| CN-116102564-A | Preparation method of azole compound and application of azole compound as antibacterial agent | 上海济煜医药科技有限公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2021112251-A1 | AZETIDINE SULFONAMIDE COMPOUND | 第一三共株式会社 | 2021-06-10 | — | — | WO | disclosed |
| US-9512126-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-12-06 | — | — | US | disclosed |
| EP-2825540-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| EP-3007698-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-20150104526-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| EP-2825540-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2015-01-21 | — | — | EP | disclosed |
| WO-2011016576-A1 | ALANINE DERIVATIVES AS INHIBITORS OF APOPTOSIS PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | WO | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010049841-A1 | 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | PFIZER INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20090270247-A1 | IN SITU OLEFIN POLYMERIZATION CATALYST SYSTEM | PROMERUS LLC (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009132240-A2 | IN SITU OLEFIN POLYMERIZATION CATALYST SYSTEM | PROMERUS LLC (US) | 2009-10-29 | — | — | WO | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BUB1, BUB1B, CDK1 | CES2 2460/4885CES1 802/4885BCHE 2749/4885 |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | FAAH, FAAH2, APEH | CES2 1035/4885CES1 226/4885BCHE 363/4885 |
| US-20150104526-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | VEGFA, CCND2, FLT4 | CES2 3272/4885CES1 1984/4885BCHE 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.